205 - Debating the Incorporation of Novel Therapies in Front-Line Acute Lymphoblastic Leukemia Treatment

Session Description: Recently, numerous studies have been published regarding the treatment of B-cell acute lymphoblastic leukemia (B-ALL) with novel agents in earlier lines of therapy. Blinatumomab, a bispecific CD19-directed CD3 T-cell engager, is currently FDA approved for relapsed/refractory B-ALL and minimal residual disease (MRD) positive B-ALL. Inotuzumab ozogamicin, a CD22-directed monoclonal antibody drug-conjugate, is approved for relapsed/refractory B-ALL. However, recent publications have demonstrated benefit for blinatumomab in the front-line setting for Ph+ ALL and in consolidation for Ph- ALL. Furthermore, data have explored the use of inotuzumab ozogamicin in combination with chemotherapy in the frontline setting for Ph- B-ALL. In a fun pro-con debate style, we will describe the impact of this data and how to incorporate novel agents like blinatumomab and inotzumab ozogamicin in the front-line treatment of B-ALL.